ロード中...
Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
INTRODUCTION: Teneligliptin, an antihyperglycemic agent belonging to the dipeptidyl peptidase-4 inhibitor class, is usually prescribed at a dose of 20 mg/day. In Japan, the dose can be increased to 40 mg/day if needed. We examined the treatment response when the teneligliptin dose was increased from...
保存先:
| 出版年: | Diabetes Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6104275/ https://ncbi.nlm.nih.gov/pubmed/29435909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0372-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|